semaglutide fda update What's New in Obesity Treatment? Compounded Semaglutide & Tirzepatide 2025:

Today, Gubra A/S (Company), a company specializing in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases, announced a collaboration with Amylyx Pharmaceuticals, Inc

Clinically studied probiotic strains for metabolic health, cravings, waist support, GLP-1 support, and sustainable weight management

Its difficult to scroll through social media or watch the news without hearing about GLP-1s

Czy analogi GLP-1 to tylko hollywoodzki lek na odchudzanie gwiazd

Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial (Lancet)